Krystal Biotech to Present at William Blair Biotech Focus Conference 2022
Krystal Biotech (NASDAQ: KRYS), a leader in redosable gene therapy, will participate in the William Blair Biotech Focus Conference 2022 on July 12-13 in New York.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Krystal Biotech (NASDAQ: KRYS), a leader in redosable gene therapy, will participate in the William Blair Biotech Focus Conference 2022 on July 12-13 in New York. CEO Krish Krishnan will engage in a fireside chat and lead investor meetings on July 13. A webcast of the event will be available starting 9 AM ET on July 11. The company focuses on developing innovative therapies for serious diseases, particularly rare skin and lung conditions. For more information, visit Krystal Biotech's website.
Details
News Market Reaction – KRYS
The recorded move for KRYS in the trading session of this news was +4.74%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
PITTSBURGH, July 06, 2022 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. (the “Company”) (NASDAQ: KRYS), the leader in redosable gene therapy, announced today that the Company will participate in the William Blair Biotech Focus Conference 2022 taking place in New York from July 12-13.
Krish Krishnan, Chairman and Chief Executive Officer, will participate in a fireside chat during the conference and host investor meetings on July 13.
A webcast of the event will be available here beginning at 9am ET on July 11 and posted on the Investor section of the Company’s website.
About Krystal Biotech, Inc.
Krystal Biotech, Inc. (NASDAQ: KRYS) is a pivotal-stage gene therapy company leveraging its proprietary, redosable gene therapy platform and in-house manufacturing capabilities to develop life-changing medicines for patients with serious diseases, including rare diseases in skin, lung, and other areas. For more information please visit http://www.krystalbio.com, and follow @KrystalBiotech on LinkedIn and Twitter.
CONTACTS:
Investors and Media:
Meg Dodge
Krystal Biotech
mdodge@krystalbio.com
Source: Krystal Biotech, Inc.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.